ALUNBRIG (brigatinib) our second approved medicine

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

4/28/17
Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib)
Read More
2/16/17
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
Read More

TWITTER FEED